Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA4 | P54764 | 2/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ILK | Q13418 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360787 | 0.93 | EPHA4 (0.53) | EPHA4ILK | |
| SCHEMBL13329337 | 0.87 | EPHA4 (0.56) | EPHA4HSP90AB1TLR8ACHEILK | |
| SCHEMBL13360799 | 0.82 | ABL1 (0.38) | EPHA4 | |
| SCHEMBL13360783 | 0.81 | EPHA4 (0.34) | EPHA4ILK | |
| SCHEMBL13329564 | 0.81 | EPHA4 (0.45) | EPHA4HSP90AB1TLR8ACHEILK | |
| SCHEMBL13360769 | 0.81 | HTR7 (0.38) | EPHA4 | |
| SCHEMBL13360811 | 0.80 | EPHA4 (0.36) | EPHA4ACHE | |
| SCHEMBL13329341 | 0.79 | EPHA4 (0.66) | EPHA4ACHEILK | |
| SCHEMBL13360788 | 0.76 | EPHA4 (0.48) | EPHA4ACHE | |
| SCHEMBL13360842 | 0.76 | EGFR (0.37) | EPHA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | EPHA4 1/4885HSP90AB1 3293/4885TLR8 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.